VEGFA and renal cell carcinoma: Axitinib a vascular endothelial growth factor (VEGF) TKI and Pembrolizumab an ICI are effective for advanced RCC; however, is there are known to have vasculogenic effects and immune-related events including fulminant myocarditis [2, 3].